Puma Biotechnology (PBYI) Total Non-Current Liabilities (2020 - 2025)

Puma Biotechnology has reported Total Non-Current Liabilities for 6 years, with the latest figure at $86.0 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 29.01% year-over-year to $86.0 million; the trailing twelve-month figure through Dec 2025 stood at $86.0 million (down 29.01% YoY), and the FY2025 full-year result was $86.0 million, down 29.01% from the prior year.
• Total Non-Current Liabilities for Q4 2025 stood at $86.0 million, down from $87.6 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $241.1 million in Q1 2021, with the low at $86.0 million in Q4 2025.
• Historically, Total Non-Current Liabilities has averaged $164.2 million across 5 years, with a median of $163.0 million in 2023.
• Annual changes were most pronounced in 2021 — Total Non-Current Liabilities increased 2.13% — and 2025, when it sank 42.32%.
• Puma Biotechnology's Total Non-Current Liabilities stood at $229.0 million in 2021, then retreated by 15.69% to $193.1 million in 2022, then declined by 8.34% to $177.0 million in 2023, then slumped by 31.58% to $121.1 million in 2024, then decreased by 29.01% to $86.0 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $86.0 million (Q4 2025), $87.6 million (Q3 2025), and $90.2 million (Q2 2025), per Business Quant data.